Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sue Douglas

Dermatology Mission Woods, KS Medical Doctor

NPI 1497750731 CMS profile 248925

2001 Shawnee Mission Pkwy Ste 130, Mission Woods, KS 66205

Open in the dashboard

General payments

$4,580

249 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sue Douglas of Mission Woods, KS is reported in the CMS Open Payments database as having received $4,580 across 249 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,007 62
2024 General $910 48
2023 General $872 46
2022 General $670 45
2021 General $492 31
2020 General $457 13
2019 General $172 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sue Douglas
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Sue Douglas were reported at $1,007. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Sue Douglas Dermatology median Middle half National median
2019 $172 $454 $129–$1,240 $163
2020 $457 $235 $81–$756 $114
2021 $492 $377 $108–$1,108 $132
2022 $670 $514 $143–$1,391 $149
2023 $872 $607 $159–$1,674 $160
2024 $910 $751 $204–$1,903 $164
2025 $1,007 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $714 38 payments
  2. Pfizer Inc. $517 25 payments
  3. Galderma Laboratories, L.P. $396 40 payments
  4. AbbVie, Inc. $377 21 payments
  5. Regeneron Healthcare Solutions, Inc. $300 10 payments
  6. Genzyme Corporation $288 14 payments
  7. Mayne Pharma Inc. $265 28 payments
  8. Incyte Corporation $250 13 payments
  9. Journey Medical Corporation $199 5 payments
  10. Sanofi-Aventis U.S. LLC $199 2 payments
  11. Other $1,075 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,316 244 payments
  2. Education $264 5 payments
Products named General payments · program years 2019–2025
  1. TALTZ $714 38 payments
  2. DUPIXENT Immunology $529 18 payments
  3. EUCRISA $366 19 payments
  4. CIBINQO $299 13 payments
  5. RINVOQ $278 14 payments
  6. DUPIXENT Inflammation And Immunology $273 9 payments
  7. EBGLYSS $261 12 payments
  8. OPZELURA $250 13 payments
  9. LITFULO $136 5 payments
  10. OLUMIANT $131 7 payments
  11. Other $1,601 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

249 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record